Abstract: Ovarian cancer is the most fatal gynecologic malignant tumor. Because of its insidious onset, difficulty diagnosis in early stage, and has the characteristics of easy early metastasis, easy recurrence and resistance to chemotherapeutic drugs, it makes the mortality of patients with ovarian cancer very high. The application of immunotherapy in ovarian cancer has been a research focus in recent years. It plays an important role in killing tumor cells by enhancing the function of the patients′ immune cells or relieving the local immunosuppressive microenvironment. PD-1 and its ligand PD-L1 are important immune regulatory signaling molecules. PD-1/PD-L1 signaling pathway can affect T lymphocyte infiltration and function, and play an important role in the formation of local inhibitory immune microenvironment. Studies have shown that blocking the PD-1/PD-L1 signaling pathway can restore immune function of immune cells in the microenvironment to play the original antitumor function. Now we review the prognosis of PD-1/PD-L1 molecules in ovarian cancer and the application of molecular pathway blocking in the clinical diagnosis and treatment of ovarian cancer.

Key words: Ovarian neoplasms, Immunotherapy, Drug resistance, neoplasm, PD-1/PD-L1